GOOD FUTURE BIOMEDICAL TECHNOLOGY CORP.
Update：2026/09/15
Industries
Main Industry
Health Care
Main Product/Service
1. Chiline CATCH® Automated Circulating Tumor Cell Detection System
2. Chiline CATCH® Circulating Tumor Cell Reagent/Consumable Kit
3. CellMag Magnetic Stand / PowerMag High-Performance Magnetic Column
4. Chiline Circulating Tumor Cell Detection
(The content above was translated by AI.)
2. Chiline CATCH® Circulating Tumor Cell Reagent/Consumable Kit
3. CellMag Magnetic Stand / PowerMag High-Performance Magnetic Column
4. Chiline Circulating Tumor Cell Detection
(The content above was translated by AI.)
Founded Year
2017
Unified Business No.
52590055
Status
Active
Number of Employees
0
Total Paid-in
Capital
143,967,000 (NT$)
Location of Company
Taiwan
, Taoyuan City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
GOOD FUTURE BIOMEDICAL TECHNOLOGY CORP. was established in 2017 and is composed of a group of partners who are passionate about clinical testing and biomedical development. Our mission is to insist on high-quality clinical testing services at affordable prices, and we are dedicated to caring for and giving back to society. Spanning an area of 100 pings, the GOOD FUTURE BIOMEDICAL TECHNOLOGY CORP. Precision Medicine Laboratory provides circulating tumor cell detection services and third-generation sequencing detection services. In addition, we continuously innovate and develop various precision medical services required in the biomedical field, hoping to provide customers with diverse choices.
(The content above was translated by AI.)
(The content above was translated by AI.)
